Skip to main content

A Study of Dapansutrile Plus Pembrolizumab in Patients with PD-1 Refractory Advanced Melanoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Olatec Therapeutics LLC

Start Date

August 10, 2022

End Date

August 14, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Olatec Therapeutics LLC

Start Date

August 10, 2022

End Date

August 14, 2027